<DOC>
	<DOC>NCT01359462</DOC>
	<brief_summary>For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.</brief_summary>
	<brief_title>Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis</brief_title>
	<detailed_description>This study is to evaluate the multiple-dose pharmacokinetics, pharmacological actions and safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in Chinese adult patients with confirmed Child-Pugh Class B（score 7-9） hepatocirrhosis (accompanied by ascites). Trial Design: 1. Open, single-center, multi-dose pharmacokinetics study 2. Study population: Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis (accompanied by ascites) 3. Dosage and mode of administration of investigational product: Oral administration of 1 tablet (15mg) once daily, for consecutive 7 days starting from day 1 of treatment. 4. Study duration: Screening: 14 days in maximum; Treatment(s): 7 days; Observation: 1 day</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1. Hepatic Cirrhosis with ascites or lower extremities edema 2. Hospitalized patients 3. 18 years old~75 years old 4. Inform Consent Form Signed 1. Patients with any of the following diseases, complications or symptoms: Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above); Malignant ascites; Spontaneous bacterial peritonitis; Likely to have gastrointestinal bleeding during the study period; Heart failure (NYHA Note 2 Class Ⅲ andⅣ); Anuria (daily urine output below 100mL); Dysuria induced by urinary tract stenosis, calculus, or tumor. 2. Patients with any of the following history: With gastrointestinal bleeding within 10 days prior to screening; With cerebrovascular accident within 1 month prior to screening; With gout attack within 1 month prior to screening; With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.). 3. Patients whose systolic blood pressure is below 90mmHg during screening; 4. Patients with abnormal values in the following lab examination indicators: Serum creatinine higher than 2.5 times the upper limit of normal range, serum Na+&gt;145mmol/L(or higher than the upper limit of normal range), serum K+&gt; 5.5 mmol/L, uric acid&gt;476µmol/L, childPugh score&gt;10 5. Patients ineligible for oral medication 6. Patients in pregnancy or lactation; female of childbearing potential not taking contraceptive measures; 7. Patients having taken blood products including albumin products within 4 days prior to application of investigational product; 8. Patients having participated in clinical trials of other drugs within 1 month prior to screening; 9. Patients used to participate in clinical trials of Tolvaptan and take the said drug; 10. Patients determined by the investigator as illegible for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>hepatic cirrhosis patients with ascites</keyword>
</DOC>